Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022982 | 1.00 | KMO (0.59) | KMOTSHRHSD11B1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL745592 | 0.98 | KMO (0.60) | KMOTSHRHSD11B1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL30062390 | 0.98 | KMO (0.60) | KMOTSHRHSD11B1HDAC3HDAC4 | |
| Bromide SCHEMBL1444256 | 0.98 | KMO (0.57) | KMOTSHRHSD11B1HDAC3HDAC4 | |
| SCHEMBL10744419 | 0.84 | KDM4E (0.51) | KMOTSHRKDM4EALDH1A1HPGD | |
| SCHEMBL9015106 | 0.83 | TSHR (0.61) | KMOTSHRHSD11B1HDAC3HDAC4 | |
| SCHEMBL18562167 | 0.82 | KMO (0.42) | KMOTSHRHSD11B1HDAC3HDAC4 | |
| SCHEMBL1443571 | 0.82 | CYP1A2 (0.51) | KMOTSHRHDAC3HDAC4HDAC1 | |
| SCHEMBL22570695 | 0.82 | KCNQ3 (0.43) | KMOTSHRALDH1A1HTT | |
| SCHEMBL13116542 | 0.82 | KCNQ3 (0.45) | KMOTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022167866-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| EP-3230274-B1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | Bayer Pharma AG (DE) | 2019-01-30 | — | — | EP | disclosed |
| US-10023539-B2 | Aryl-cyanoguanidine compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-10023539-B2 | Aryl-cyanoguanidine compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-07-17 | — | — | US | disclosed |
| US-20180118722-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118722-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| EP-2429296-A1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110224267-A1 | Selective androgen receptor modulators | Radius Health,Inc. (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2010132442-A1 | 7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESERCH, INC. (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132487-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292250-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100292243-A1 | 7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7501446-B2 | Prenylation inhibitors and methods of their synthesis and use | PPD DISCOVERY, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | PHARMACEUTICAL PRODUCT DEVELOPMENT, LLC | 2007-06-28 | — | — | US | disclosed |
| US-4379929-A | BACTERIOSTATS | ELI LILLY AND COMPANY (US) | 1983-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292250-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF | UACA, SCN1A, NLN | KMO 1227/4885TSHR 3159/4885HSD11B1 3708/4885 |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | KMO 49/4885TSHR 1373/4885HSD11B1 1142/4885 |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | KMO 1818/4885TSHR 2579/4885HSD11B1 4045/4885 |
| US-20110224267-A1 | Selective androgen receptor modulators | AR, SHBG, GPR119 | KMO 2459/4885TSHR 512/4885HSD11B1 201/4885 |
| US-20100292243-A1 | 7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | CIAPIN1, CLN6, SCN1A | KMO 908/4885TSHR 3115/4885HSD11B1 3542/4885 |
| US-20070149549-A1 | 3-(Pyrid-3-yl)-5-(thiophen-2-yl)-pyrazoles; prenyl-protein transferase inhibitors | FNTA, PTAR1, ZMPSTE24 | KMO 2796/4885TSHR 3501/4885HSD11B1 1240/4885 |
| US-20180118722-A1 | NOVEL ARYL-CYANOGUANIDINE COMPOUNDS | SMYD2, SETD2, SMYD3 | KMO 287/4885TSHR 3562/4885HSD11B1 3834/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | KMO 2128/4885TSHR 2069/4885HSD11B1 1193/4885 |
| US-10023539-B2 | Aryl-cyanoguanidine compounds | SMYD2, SETD2, SMYD3 | KMO 286/4885TSHR 3348/4885HSD11B1 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.